Hemoglobinopathies Market Size, Statistics, Forecast 2022-2027
The latest research study “Hemoglobinopathies Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027” by IMARC Group, finds that the global hemoglobinopathies market size reached a value of US$ 8.36 Billion in 2021. Looking forward, the market expected to reach a value of US$ 14.8 Billion by 2027 exhibiting a CAGR of 9.50% during 2022-2027.
Hemoglobinopathies refer to a group of genetic blood diseases that cause abnormality in the structure and synthesis of hemoglobin molecules. Some common types of hemoglobinopathies include sickle cell, thalassemia, hemoglobin C, and beta-thalassemia. They are detected by normal red blood cell (RBC) count, hemoglobin isoelectric focusing (Hb IEF), genetic testing, hemoglobin by high-performance liquid chromatography, and hemoglobin electrophoresis (Hb ELP) test. Some common symptoms of hemoglobinopathies include pale skin, shortness of breath, cold hands or feet, tiredness, pain, and swelling in the hands and feet. At present, hemoglobinopathies can be treated using antibiotics, ACE inhibitors, stem-cell transplantation, blood transfusions, hydroxyurea, and analgesic.
Download a Free PDF Sample for more detailed market insights: https://www.imarcgroup.com/hemoglobinopathies-market/requestsample
Hemoglobinopathies Market Trends and Drivers:
The global hemoglobinopathies market is primarily driven by the increasing prevalence of numerous medical conditions, such as sickle cell disease (SCD) and thalassemia. Moreover, numerous technological developments, such as the introduction of CRISPR-Cas9 technology to treat hemoglobinopathies by adding, removing, or altering genes and modifying the DNA, are contributing to the market growth.
In addition, the surging adoption of gene therapy for treating hemoglobinopathies is positively influencing the market growth. Additionally, hemoglobinopathies are caused by abnormal hemoglobin that deforms and destroys red blood cells, making them hard and sticky. In line with this, the increasing prevalence of anemia, especially among the geriatric population, has catalyzed market growth.
Other factors, including favorable government initiatives to introduce novel therapies for treating hemoglobinopathies at affordable cost, rapid expansion in the healthcare industry, and rising medical expenditure, are also anticipated to propel the market growth.
Note: We are in the process of updating our reports. If you want to receive the latest research data covering the time period from 2023 to 2028, along with industry trends, market size, and competitive analysis, click on the request sample report. The team would be able to deliver the latest version of the report in a quick turnaround time.
Global Hemoglobinopathies Market 2022-2027 Analysis and Segmentation:
Competitive Landscape:
The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market.
Hemoglobinopathies Companies:
Bio-Rad Laboratories Inc., bluebird bio Inc., Bristol-Myers Squibb Company, Danaher Corporation, Emmaus Life Sciences Inc., Gamida-Cell Ltd., Global Blood Therapeutics Inc., Novartis AG, PerkinElmer Inc., Pfizer Inc., Prolong Pharmaceuticals LLC, Sangamo Therapeutics Inc. and Sysmex Corporation.
The report has segmented the market on the basis of region, type, treatment, test type and end user.
Breakup by Type:
· Thalassemia
o Alpha Thalassemia
o Beta Thalassemia
· Sickle Cell Disease
· Others
Breakup by Treatment:
· Blood Transfusion
· Stem-cell Transplantation
· Analgesics
· Antibiotics
· ACE Inhibitors
· Hydroxyurea
· Others
Breakup by Test Type:
· Red Blood Cell (RBC) Count
· Genetic Testing
· High Performance Liquid Chromatography (HPLC)
· Hemoglobin Isoelectric Focusing (Hb IEF)
· Hemoglobin Electrophoresis (Hb ELP)
· Hemoglobin Solubility Test
Breakup by End User:
· Hospitals and Clinics
· Diagnostics Laboratories
· Others
Breakup by Region:
North America: (United States, Canada)
Asia Pacific: (China, Japan, India, South Korea, Australia, Indonesia, Others)
Europe: (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
Latin America: (Brazil, Mexico, Others)
Middle East and Africa
Ask Analyst for Customization and Explore Full Report with TOC & List of Figure: https://www.imarcgroup.com/request?type=report&id=5123&flag=C
If you want latest primary and secondary data (2022-2027) with Cost Module, Business Strategy, Distribution Channel, etc. Click request free sample report, published report will be delivered to you in PDF format via email within 24 to 48 hours of receiving full payment.
Key highlights of the report:
Market Performance (2016-2021)
Market Outlook (2022- 2027)
Porter’s Five Forces Analysis
Market Drivers and Success Factors
SWOT Analysis
Value Chain
Comprehensive Mapping of the Competitive Landscape
If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.
About Us:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact Us: IMARC Services Private Limited. 134 N 4th St. Brooklyn, NY 11249, USA Email: Sales@imarcgroup.com Tel No:(D) +91 120 433 0800 Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800